TrialGynecologic oncology2026

A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor.

Elizabeth E Hopp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.